DaShenLin Pharmaceutical Group Co., Ltd.
SSE:603233.SS
16.27 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 26,496.547 | 24,531.39 | 21,248.087 | 16,759.335 | 14,582.865 | 11,141.165 | 8,859.274 | 7,421.197 | 6,273.722 | 5,265.482 | 4,545.011 | 3,706.656 | 3,252.46 |
| Cost of Revenue
| 17,401.139 | 15,795.074 | 13,216.858 | 10,365.748 | 8,973.435 | 6,742.56 | 5,169.797 | 4,433.549 | 3,750.576 | 3,105.14 | 2,714.064 | 2,264.695 | 2,063.353 |
| Gross Profit
| 9,095.408 | 8,736.316 | 8,031.229 | 6,393.587 | 5,609.43 | 4,398.605 | 3,689.477 | 2,987.648 | 2,523.146 | 2,160.342 | 1,830.947 | 1,441.961 | 1,189.108 |
| Gross Profit Ratio
| 0.343 | 0.356 | 0.378 | 0.381 | 0.385 | 0.395 | 0.416 | 0.403 | 0.402 | 0.41 | 0.403 | 0.389 | 0.366 |
| Reseach & Development Expenses
| 51.683 | 87.599 | 74.378 | 44.607 | 4.701 | 0.434 | 0.496 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 303.367 | 297.129 | 282.828 | 258.331 | 178.84 | 141.036 | 126.862 | 107.443 | 98.142 | 76.909 | 76.507 | 166.304 | 135.504 |
| Selling & Marketing Expenses
| -5,301.174 | 5,653.847 | 5,186.143 | 4,291.882 | 3,498.554 | 2,920.135 | 2,495.396 | 1,933.289 | 1,575.781 | 1,301.4 | 1,123.296 | 904.271 | 763.207 |
| SG&A
| -4,997.807 | 5,950.976 | 5,468.971 | 4,550.213 | 3,677.395 | 3,061.171 | 2,622.258 | 2,040.731 | 1,673.923 | 1,378.309 | 1,199.803 | 1,070.575 | 898.711 |
| Other Expenses
| 12,687.442 | 1,143.573 | 822.991 | 603.887 | 480.524 | 388.35 | 1.258 | 1.26 | 27.595 | 7.148 | 49.078 | 7.262 | 3.239 |
| Operating Expenses
| 7,741.319 | 7,175.477 | 6,366.341 | 5,198.707 | 4,162.62 | 3,449.955 | 2,950.319 | 2,319.287 | 1,908.109 | 1,581.009 | 1,377.419 | 1,099.2 | 925.343 |
| Operating Income
| 1,354.089 | 1,631.843 | 1,420.794 | 1,040.534 | 1,447.962 | 918.256 | 718.298 | 633.316 | 578.552 | 547.873 | 411.363 | 315.614 | 241.268 |
| Operating Income Ratio
| 0.051 | 0.067 | 0.067 | 0.062 | 0.099 | 0.082 | 0.081 | 0.085 | 0.092 | 0.104 | 0.091 | 0.085 | 0.074 |
| Total Other Income Expenses Net
| -14.416 | -4.058 | -5.9 | 3.379 | -1.552 | 1.241 | 1.258 | 1.26 | -0.883 | 6.334 | 12.319 | 6.02 | -20.243 |
| Income Before Tax
| 1,339.673 | 1,627.785 | 1,414.895 | 1,043.913 | 1,446.41 | 919.498 | 719.556 | 634.576 | 577.471 | 554.208 | 423.682 | 321.635 | 243.522 |
| Income Before Tax Ratio
| 0.051 | 0.066 | 0.067 | 0.062 | 0.099 | 0.083 | 0.081 | 0.086 | 0.092 | 0.105 | 0.093 | 0.087 | 0.075 |
| Income Tax Expense
| 359.73 | 397.124 | 335.621 | 239.518 | 363.391 | 222.955 | 193.868 | 159.965 | 148.858 | 131.948 | 115.351 | 96.285 | 72.145 |
| Net Income
| 914.755 | 1,166.498 | 1,035.724 | 791.231 | 1,062.181 | 702.662 | 531.634 | 474.961 | 430.189 | 395.434 | 265.502 | 197.382 | 149.183 |
| Net Income Ratio
| 0.035 | 0.048 | 0.049 | 0.047 | 0.073 | 0.063 | 0.06 | 0.064 | 0.069 | 0.075 | 0.058 | 0.053 | 0.046 |
| EPS
| 0.81 | 1.03 | 0.91 | 0.7 | 0.94 | 0.63 | 0.49 | 0.47 | 0.44 | 0.46 | 0.36 | 0.27 | 0.29 |
| EPS Diluted
| 0.81 | 1.03 | 0.91 | 0.7 | 0.94 | 0.53 | 0.49 | 0.47 | 0.44 | 0.46 | 0.36 | 0.27 | 0.29 |
| EBITDA
| 3,026.043 | 3,141.619 | 2,751.246 | 2,649.789 | 1,825.385 | 1,267.365 | 1,005.307 | 730.738 | 655.272 | 680.194 | 541.705 | 342.761 | 263.765 |
| EBITDA Ratio
| 0.114 | 0.128 | 0.129 | 0.158 | 0.125 | 0.114 | 0.113 | 0.098 | 0.104 | 0.129 | 0.119 | 0.092 | 0.081 |